1. The role of immune regulatory molecules in multiple sclerosis.
- Author
-
Afshar, Boshra, Khalifehzadeh-Esfahani, Zahra, Seyfizadeh, Narges, Rezaei Danbaran, Gholamreza, Hemmatzadeh, Maryam, and Mohammadi, Hamed
- Subjects
- *
MYELIN sheath diseases , *MULTIPLE sclerosis , *MYELIN oligodendrocyte glycoprotein , *MOLECULES , *CENTRAL nervous system , *T cells , *IMMUNE response - Abstract
Multiple sclerosis (MS) is the most common demyelinating disease which mainly impacts the integrity of central nervous system (CNS). MS etiology is not clearly known but genetic, environmental factors and immune system are the most frequently explored risk factors. Adaptive immune responses have a critical role in MS pathogenesis in which auto-reactive T-cells and autoantibodies are main orchestrators. Immune responses are modulated by inhibitory molecules which regulates adaptive system activation and hemostasis interface. These molecules suppress immune responses through inhibition of cytokine secretion and T cell proliferation and subsequently reducing the inflammation and respective damage. Therefore the critical role of inhibitory molecules in regulating the healthy and safe immune responses make them very attractive target for immunotherapy. In this review paper, the role of inhibitory molecules expressed on the various immune cell types in MS pathogenesis and experimental autoimmune encephalomyelitis (EAE) animal model will be summarized. • VISTA is one of the goals in the therapeutic target for MS treatment. • CTLA-4 polymorphisms do not correlate with MS susceptibility. • Modulating Lag-3 can affect the autoimmune disease as well as MS. • TIM3–galectin-9 pathway associated with auto-reactive T cells. • Modulation of PD1 and PD-L1 pathways holds promise in MS therapeutic potential. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF